痛风与尿酸代谢相关的肠道及肠道外菌群调控机制的研究进展
收稿日期: 2025-08-04
修回日期: 2025-09-23
录用日期: 2025-10-15
网络出版日期: 2026-04-08
基金资助
国家自然科学基金项目(32270947);云南省“万人计划”专项培养计划任务(YN-WR-MY-2018-040);云南省卫生健康委员会医学领军人才培养计划(L-2019004);云南省科技厅科技计划项目(202301AY070001-159);云南省“万人计划”青年拔尖人才(YNWR-QNBJ-2018-152);昆明医科大学第一附属医院“535”高层次人才青年学术骨干(2022535Q01);白求恩·普爱医学研究基金(PAYJ-043);云南省临床医学中心科研项目(YWLCYXZX2023300076);云南省临床医学中心科研项目(2024YNLCYXZX0019);云南省临床医学中心科研项目(2024YNLCYXZX0031);云南省临床医学中心科研项目(2024YNLCYXZX0042);昆明医科大学2025年研究生教育创新基金(2025S042)
版权
Research progress on the regulatory mechanisms of gut and extraintestinal microbiota in gout and uric acid metabolism
Received date: 2025-08-04
Revised date: 2025-09-23
Accepted date: 2025-10-15
Online published: 2026-04-08
Copyright
痛风是一种以尿酸代谢紊乱为特征的自身炎症代谢性疾病。近年来，宏基因组学的进展推动了痛风相关菌群研究的深入，尤其关注肠道、口腔、尿液菌群及其对尿酸代谢的调控作用。痛风相关肠道菌群失衡表现为益生菌减少、机会致病菌增加，可通过影响尿酸代谢酶、尿酸转运蛋白、肠道屏障功能及炎症信号通路，进而调控尿酸生成与排泄。同时，口腔和尿液菌群的初步研究提示其可能不仅作为生物标志物，还通过“口腔-肠道迁移”及尿液菌群改变等途径参与痛风的炎症反应。微生态干预，包括益生元、益生菌、菌群移植及中药活性成分，可通过改善菌群稳态、促进肾外尿酸排泄及减轻炎症，为痛风管理提供潜在的临床转化价值。未来研究应进一步阐明菌群与痛风的因果关系，开发精准的微生态干预策略，为个性化治疗和疾病管理提供理论依据与实践指导。
刘志成 , 陈银子 , 杨一帆 , 徐健 , 刘爽 . 痛风与尿酸代谢相关的肠道及肠道外菌群调控机制的研究进展[J]. 内科理论与实践, 2026 , 21(01) : 85 -90 . DOI: 10.16138/j.1673-6087.2026.01.13
Gout is an autoinflammatory metabolic disorder characterized by dysregulation of uric acid metabolism. Recent advances in metagenomics have propelled in-depth research on gout-associated microbiota, with particular attention to the gut, oral, urinary microbiota and their regulatory roles in uric acid metabolism. Dysbiosis of the gout-related gut microbiota is typified by a reduction in probiotics and an increase in opportunistic pathogens, which can regulate uric acid production and excretion by affecting urate-metabolizing enzymes, urate transporters, intestinal barrier function, and inflammatory signaling pathways. Meanwhile, preliminary studies on oral and urinary microbiota suggest that they may not only serve as biomarkers but also participate in the inflammatory response of gout through mechanisms such as “oral-gut translocation” and alterations in urinary microbiota. Microecological interventions—including prebiotics, probiotics, microbiota transplantation, and bioactive compounds derived from traditional Chinese medicine—hold potential clinical translational value in gout management by improving microbial homeostasis, promoting extra-renal urate excretion, and alleviating inflammation. Future research should further elucidate the causal relationship between microbiota and gout, and develop precise microecological intervention strategies to provide theoretical basis and practical guidance for personalized treatment and disease management.
Key words： gout; hyperuricemia; gut microbiota; oral microbiota; urinary microbiota; uric acid metabolism
| [1] | Dalbeth N, Gosling AL, Gaffo A, et al. Gout[J]. Lancet, 2021, 397(10287):1843-1855. |
| [2] | Pascart T, Lioté F. Gout: state of the art after a decade of developments[J]. Rheumatology (Oxford), 2019, 58(1):27-44. |
| [3] | Song J, Jin C, Shan Z, et al. Prevalence and risk factors of hyperuricemia and gout: a cross-sectional survey from 31 provinces in mainland China[J]. J Transl Int Med, 2022, 10(2):134-145. |
| [4] | Wang Y, Li W, Wu H, et al. Global status and trends in gout research from 2012 to 2021: a bibliometric and visual analysis[J]. Clin Rheumatol, 2023, 42(5):1371-1388. |
| [5] | Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans[J]. Cell, 2016, 164(3):337-340. |
| [6] | Chu Y, Sun S, Huang Y, et al. Metagenomic analysis revealed the potential role of gut microbiome in gout[J]. NPJ Biofilms Microbiomes, 2021, 7(1):66. |
| [7] | Grelska A, Sharan D, Light SH. Purine-ifying uric acid by gut microbes[J]. Cell Chem Biol, 2023, 30(7):706-708. |
| [8] | Guo Z, Zhang J, Wang Z, et al. Intestinal microbiota distinguish gout patients from healthy humans[J]. Sci Rep, 2016, 6:20602. |
| [9] | Shao T, Shao L, Li H, et al. Combined signature of the fecal microbiome and metabolome in patients with gout[J]. Front Microbiol, 2017, 8:268. |
| [10] | Méndez-Salazar EO, Vázquez-Mellado J, Casimiro-Soriguer CS, et al. Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism[J]. Mol Med, 2021, 27(1):50. |
| [11] | Cao C, Fan B, Zhu J, et al. Association of gut microbiota and biochemical features in a Chinese population with renal uric acid stone[J]. Front Pharmacol, 2022, 13:888883. |
| [12] | Park HK, Lee SJ. Treatment of gouty arthritis is associated with restoring the gut microbiota and promoting the production of short-chain fatty acids[J]. Arthritis Res Ther, 2022, 24(1):51. |
| [13] | Ul-Haq A, Lee KA, Seo H, et al. Characteristic alterations of gut microbiota in uncontrolled gout[J]. J Microbiol, 2022, 60(12):1178-1190. |
| [14] | Wei J, Zhang Y, Dalbeth N, et al. Association between gut microbiota and elevated serum urate in two independent cohorts[J]. Arthritis Rheumatol, 2022, 74(4):682-691. |
| [15] | Kim HW, Yoon EJ, Jeong SH, et al. Distinct gut microbiota in patients with asymptomatic hyperuricemia: a potential protector against gout development[J]. Yonsei Med J, 2022, 63(3):241-251. |
| [16] | Yuan X, Chen R, Zhang Y, et al. Altered gut microbiota in children with hyperuricemia[J]. Front Endocrinol (Lausanne), 2022, 13:848715. |
| [17] | Wang M, Fan J, Huang Z, et al. Causal relationship between gut microbiota and gout: a two-sample Mendelian randomization study[J]. Nutrients, 2023, 15(19):4260. |
| [18] | Lou Y, Liu B, Jiang Z, et al. Assessing the causal relationships of gut microbial genera with hyperuricemia and gout using two-sample Mendelian randomization[J]. Nutr Metab Cardiovasc Dis, 2024, 34(4):1028-1035. |
| [19] | Chen C, Zhang Y, Yao X, et al. Characterizations of the multi-kingdom gut microbiota in Chinese patients with gouty arthritis[J]. BMC Microbiol, 2023, 23(1):363. |
| [20] | Steunou AS, Babot M, Durand A, et al. Discriminating susceptibility of xanthine oxidoreductase family to metals[J]. Microbiol Spectr, 2023, 11(4):e0481422. |
| [21] | Xi H, Schneider BL, Reitzer L. Purine catabolism in Escherichia coli and function of xanthine dehydrogenase in purine salvage[J]. J Bacteriol, 2000, 182(19):5332-5341. |
| [22] | Wu XW, Lee CC, Muzny DM, et al. Urate oxidase: primary structure and evolutionary implications[J]. Proc Natl Acad Sci U S A, 1989, 86(23):9412-9416. |
| [23] | Sun L, Zhang M, Zhao J, et al. The human gut microbiota and uric acid metabolism: genes, metabolites, and diet[J]. Crit Rev Food Sci Nutr, 2025, 65(31):7612-7632. |
| [24] | Liu Y, Jarman JB, Low YS, et al. A widely distributed gene cluster compensates for uricase loss in hominids[J]. Cell, 2023, 186(16):3400-3413. |
| [25] | Tang Y, Du Y, Ye J, et al. Intestine-targeted explosive hydrogel microsphere promotes uric acid excretion for gout therapy[J]. Adv Mater, 2024, 36(3):e2310492. |
| [26] | Yin H, Liu N, Chen J. The role of the intestine in the development of hyperuricemia[J]. Front Immunol, 2022, 13:845684. |
| [27] | Takada T, Ichida K, Matsuo H, et al. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion[J]. Nucleosides Nucleotides Nucleic Acids, 2014, 33(4-6):275-281. |
| [28] | Xie QS, Zhang JX, Liu M, et al. Short-chain fatty acids exert opposite effects on the expression and function of P-glycoprotein and breast cancer resistance protein in rat intestine[J]. Acta Pharmacol Sin, 2021, 42(3):470-481. |
| [29] | Guo Y, Yu Y, Li H, et al. Inulin supplementation ameliorates hyperuricemia and modulates gut microbiota in Uox-knockout mice[J]. Eur J Nutr, 2021, 60(4):2217-2230. |
| [30] | Yang Y, Wang Y, Huang J, et al. Influence of gut microbiota-derived butyrate on intestinal uric acid excretion and hyperuricemia regulation by Cichorium intybus L[J]. Int J Mol Sci 2025, 26(13):6413. |
| [31] | Han R, Wang Z, Li Y, et al. Gut microbiota Lactobacillus johnsonii alleviates hyperuricemia by modulating intestinal urate and gut microbiota-derived butyrate[J]. Chin Med J (Engl), 2026, 139(1):118-135. |
| [32] | Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation[J]. Arthritis Rheum, 2005, 52(9):2936-2946. |
| [33] | Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression[J]. J Immunol, 2009, 183(2):787-791. |
| [34] | Martínez-Nava GA, Méndez-Salazar EO, Vázquez-Mellado J, et al. The impact of short-chain fatty acid-producing bacteria of the gut microbiota in hyperuricemia and gout diagnosis[J]. Clin Rheumatol, 2023, 42(1):203-214. |
| [35] | Lin X, Shao T, Wen X, et al. Combined effects of MSU crystals injection and high fat-diet feeding on the establishment of a gout model in C57BL/6 mice[J]. Adv Rheumatol, 2020, 60(1):52. |
| [36] | Xi Y, Yan J, Li M, et al. Gut microbiota dysbiosis increases the risk of visceral gout in goslings through translocation of gut-derived lipopolysaccharide[J]. Poult Sci, 2019, 98(11):5361-5373. |
| [37] | Song S, Lou Y, Mao Y, et al. Alteration of gut microbiome and correlated amino acid metabolism contribute to hyperuricemia and Th17-driven inflammation in Uox-KO mice Front Immunol 2022, 13:804306. |
| [38] | Song S, Fan M, Wen X, et al. Integrated network pharmacology and gut microbiome analysis to reveal the mechanism of Qu-Zhuo-Tong-Bi decoction against hyperuricemia and gout[J]. J Ethnopharmacol, 2023, 316:116736. |
| [39] | Wang M, Li R, Qi H, et al. Metabolomics and machine learning identify metabolic differences and potential biomarkers for frequent versus infrequent gout flares[J]. Arthritis Rheumatol, 2023, 75(12):2252-2264. |
| [40] | Yamada N, Iwamoto C, Kano H, et al. Evaluation of purine utilization by Lactobacillus gasseri strains with potential to decrease the absorption of food-derived purines in the human intestine[J]. Nucleosides Nucleotides Nucleic Acids, 2016, 35(10-12):670-676. |
| [41] | Copur S, Demiray A, Kanbay M. Uric acid in metabolic syndrome: does uric acid have a definitive role?[J]. Eur J Intern Med, 2022, 103:4-12. |
| [42] | Xie XQ, Geng Y, Guan Q, et al. Influence of short-term consumption of Hericium erinaceus on serum biochemical markers and the changes of the gut microbiota: a pilot study[J]. Nutrients 2021, 13(3):1008. |
| [43] | Arora V, Singh G, O-Sullivan I, et al. Gut-microbiota modulation: The impact of the gut-microbiota on osteoarthritis[J]. Gene, 2021, 785:145619. |
| [44] | Wang H, Mei L, Deng Y, et al. Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis[J]. Nutrition, 2019, 62:63-73. |
| [45] | Wu Y, Ye Z, Feng P, et al. Limosilactobacillus fermentum JL-3 isolated from “Jiangshui” ameliorates hyperuricemia by degrading uric acid[J]. Gut Microbes, 2021, 13(1):1-18. |
| [46] | Xie WR, Yang XY, Deng ZH, et al. Effects of washed microbiota transplantation on serum uric acid levels, symptoms, and intestinal barrier function in patients with acute and recurrent gout: a pilot study[J]. Dig Dis, 2022, 40(5):684-690. |
| [47] | Wen XY, Tang XY, He D, et al. Research progress on anti-hyperuricemia effects and mechanisms of Chinese medicines based on regulation of intestinal flora and metabolites[J]. Zhongguo Zhong Yao Za Zhi, 2021, 46(24):6387-6394. |
| [48] | Liu ZQ, Sun X, Liu ZB, et al. Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity[J]. J Pharm Pharmacol, 2022, 74(7):919-929. |
| [49] | Ye LW, Zhao L, Mei ZS, et al. Association between periodontitis and uric acid levels in blood and oral fluids: a systematic review and meta-analysis[J]. BMC Oral Health, 2023, 23(1):178. |
| [50] | Chen Y, Lu P, Lin C, et al. Hyperuricemia and elevated uric acid/creatinine ratio are associated with stages Ⅲ/Ⅳ periodontitis: a population-based cross-sectional study (NHANES 2009-2014)[J]. BMC Oral Health, 2024, 24(1):1389. |
| [51] | Zhao J, Huang Y. Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy[J]. Clin Chim Acta, 2015, 450:115-120. |
| [52] | Zhou J, Jiang N, Wang Z, et al. Influences of pH and iron concentration on the salivary microbiome in individual humans with and without caries[J]. Appl Environ Microbiol, 2017, 83(4):e02412-e02416. |
| [53] | Liu J, Cui L, Yan X, et al. Analysis of oral microbiota revealed high abundance of prevotella intermedia in gout patients[J]. Cell Physiol Biochem, 2018, 49(5):1804-1812. |
| [54] | K?n?nen E, Gursoy UK. Oral Prevotella species and their connection to events of clinical relevance in gastrointestinal and respiratory tracts[J]. Front Microbiol 2022, 13:798763. |
| [55] | Stern JM, Moazami S, Qiu Y, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers[J]. Urolithiasis, 2016, 44(5):399-407. |
| [56] | Ning Y, Yang G, Chen Y, et al. Characteristics of the urinary microbiome from patients with gout: a prospective study[J]. Front Endocrinol (Lausanne), 2020, 11:272. |
| [57] | Cumpanas AA, Bratu OG, Bardan RT, et al. Urinary microbiota-are we ready for prime time? A literature review of study methods’ critical steps in avoiding contamination and minimizing biased results[J]. Diagnostics (Basel), 2020, 10(6):343. |
/
| 〈 |
|
〉 |
